William Aird/X
Jul 7, 2025, 11:42
What Drives Essential Thrombocythemia? Dr. William Aird on the Pathophysiology of Platelet Overproduction
Dr. William Aird, Professor of Medicine at Harvard Medical School, has posted on X:
“Essential Thrombocythemia (ET) Pathophysiology
ET is driven by one of 3 mutations:
- JAK2 V617F → cytokine-independent signaling
- CALR → abnormal MPL activation
- MPL → constitutive TPO receptor signaling
All lead to unchecked megakaryocyte proliferation and ↑ platelets.”
Curious about what drives Essential Thrombocythemia? Here’s a quick look at the mutations involved.
Explore more on Hemostasis Today.
-
Apr 11, 2026, 13:51David McIntosh: Vital Plasma Derived Medicines – The Anomalous UK Scene
-
Apr 11, 2026, 13:47Samrawit Terefe: O Negative Blood Is the Universal Donor With Extreme Scarcity
-
Apr 11, 2026, 13:39Dheeraj Garg: Rethinking Cardiovascular Disease – A Cardiologist’s Perspective
-
Apr 11, 2026, 13:37Kushal Bhatia: Is The 4.5-Hour Thrombolysis Window Officially Outdated?
-
Apr 11, 2026, 13:35William Aird: Why Did Mammalian Red Blood Cells Give Up Their Nucleus?
-
Apr 11, 2026, 13:30Ken Kuang: Gravity Is Constant, But Your Vein Health Doesn’t Have to Be
-
Apr 11, 2026, 13:21Mascha Kern: Measuring Gender’s Role in Stroke and Migraine
-
Apr 11, 2026, 13:10Danique Steeghs: Key Findings from a Microfluidic Chemiluminescent Thrombin Generation Assay
-
Apr 11, 2026, 13:06Shanvi Mahi: A Validated Tool to Explore Lived Experiences After Stroke Rehabilitation